Theo Sas joined Diabeter as a pediatric endocrinologist in June 2018. He graduaded (MD) and obtained his PhD in pediatric endocrinology in 1999 at the Erasmus University, Rotterdam, The Netherlands. Previous positions include pediatrician at the Department of Pediatrics of the Albert Schweitzer Hospital, Dordrecht, the Netherlands.

Dr Sas is a member of the European Society for Pediatric Endocrinology (ESPE) and secretary of the board of the ESPE’s Turner Working Group. He is also a member of the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the Dutch Society for Pediatrics, division Endocrinology (SEK), where he is chair of the Dutch Advisory Group on Growth Hormone (Adviesgroep GH) and board member of the ‘Dutch-Flemish Working Group on Turner syndrome’. Furthermore he is a member of the Dutch Working Group on diabetes mellitus (LWKDM), where he is a board member of BIDON for DPARD (Dutch registration on Diabetes Mellitus type1). Finally, he is chair ‘Netwerk Groei en Ontwikkeling’ of the Dutch Society for Endocrinology (NVE).

Selected publications include:

• • Klein KO, Rosenfield RL, Santen RJ, Gawlik AM, Backeljauw PF, Gravholt CH, Sas TCJ, Mauras N. Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations. J Clin Endocrinol Metab. 2018 May 1;103(5):1790-1803.
  • Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Söderström-Anttila V, Stochholm K, van Alfen-van derVelden JA, Woelfle J, Backeljauw PF; International Turner Syndrome Consensus Group. Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol. 2017 Sep;177(3):G1-G70.
  • Boogerd E, Maas-Van Schaaijk NM, Sas TC, Clement-de Boers A, Smallenbroek M, Nuboer R, Noordam C, Verhaak CM. Sugarsquare, a Web-Based Patient Portal for Parents of a Child With Type 1 Diabetes: Multicenter Randomized Controlled Feasibility Trial. J Med Internet Res. 2017 Aug 22;19(8):e287.
  • Freriks K, Verhaak CM, Sas TC, Menke LA, Wit JM, Otten BJ, de Muinck Keizer-Schrama SM, Smeets DF, Netea-Maier RT, Hermus AR, Kessels RP, Timmers HJ. Long-term effects of oxandrolone treatment in childhood on neurocognition, quality of life and social-emotional functioning in young adults with Turner syndrome. Horm Behav. 2015 Mar;69:59-67.
  • Verver EJ, Freriks K, Sas TC, Huygen PL, Pennings RJ, Smeets DF, Hermus AR, Menke LA, Wit JM, Otten BJ, van Alfen-van der Velden JA, de Muinck Keizer-Schrama SM, Topsakal V, Admiraal RJ, Timmers HJ, Kunst HP. Karyotype-specific ear and hearing problems in young adults with Turner syndrome and the effect of oxandrolone treatment. Otol Neurotol. 2014 Oct;35(9):1577-84.
  • Sas TC, Gault EJ, Bardsley MZ, Menke LA, Freriks K, Perry RJ, Otten BJ, de Muinck Keizer-Schrama SM, Timmers H, Wit JM, Ross JL, Donaldson MD. Safety and efficacy of oxandrolone in growth hormone-treated girls with Turner syndrome: evidence from recent studies and recommendations for use. Horm Res Paediatr. 2014;81(5):289-97.
  • Schrier L, de Kam ML, McKinnon R, Che Bakri A, Oostdijk W, Sas TC, Menke LA, Otten BJ, de Muinck Keizer-Schrama SM, Kristrom B, Ankarberg-Lindgren C, Burggraaf J, Albertsson-Wikland K, Wit JM. Comparison of body surface area versus weight-based growth hormone dosing for girls with Turner syndrome. Horm Res Paediatr. 2014;81(5):319-30.

A complete bibliography can be found here.